National Institute of Health Research Conducts Clinical Trial of COVID-19 Vaccine Candidate
[Asia Economy Reporter Hyun-ui Cho] The National Institute of Health under the Korea Disease Control and Prevention Agency announced on the 16th that it plans to conduct domestic Phase 1 and 2 clinical trials of a novel coronavirus disease (COVID-19) vaccine candidate in collaboration with the International Vaccine Institute (IVI) and others.
The National Institute of Health has been conducting clinical trials in the United States since the 6th, administering Inovio's COVID-19 vaccine candidate (INO-4800) to 40 healthy adults to analyze and evaluate safety, and plans to expand vaccination to include the elderly thereafter.
This clinical trial research is supported by $6.9 million (approximately 8.4 billion KRW) from the Coalition for Epidemic Preparedness Innovations (CEPI), an international private partnership.
The National Institute of Health and the International Vaccine Institute will analyze and evaluate essential procedures such as safety and efficacy for the clinical trials. They are also collaborating with the Ministry of Food and Drug Safety from the planning review stage to expedite the clinical trial process.
The candidate vaccine used in this clinical trial employs a DNA vaccine platform technology, which was also used for the Middle East Respiratory Syndrome (MERS) vaccine, and Phase 1 clinical trials were conducted domestically using the same platform. DNA vaccines can be rapidly developed and mass-produced by using an already proven safe platform.
Once the safety and efficacy of the candidate vaccine are evaluated in humans through global clinical trials conducted domestically and abroad, the development of a safe and effective COVID-19 vaccine is expected to accelerate.
Hot Picks Today
At President Lee's Call to "Give Enough to Shock," Whistleblower Rewards Become a Real Lottery
- If They Fail Next Year, Bonus Drops to 97 Million Won... A Closer Look at Samsung Electronics DS Division’s 600M vs 460M vs 160M Performance Bonuses
- Lived as Family for Over 30 Years... Daughter-in-Law Cast Aside After Husband's Death
- Opening a Bank Account in Korea Is Too Difficult..."Over 150,000 Won in Notarization Fees Just for a Child's Account and Debit Card" [Foreigner K-Finance Status]②
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Kim Sung-soon, Director of the Infectious Disease Research Center at the National Institute of Health, stated, “To control the global pandemic of COVID-19 and develop essential preventive vaccines, we will actively promote practical research in cooperation with the international community and expand private sector support through the Public Vaccine Development and Support Center currently under construction.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
